OncoMatch/Clinical Trials/NCT06725524
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
Is NCT06725524 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JMT601 for b-cell non hodgkin lymphoma.
Treatment: JMT601 — This is a Phase 1, open-label, multi-center study to evaluate the safety of JMT601 in the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma and to determine the recommended dose for Phase 2 studies (RP2D). Study consists of 2 parts. The first part is a dose-escalation part using a 3+3 design with up to 6 dose(0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 12 mg/kg and 20 mg/kg) escalation cohorts at increasing levels. The second part is a dose-expansion part at R2PD dose to assess preliminary efficacy of JMT601.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20-positive)
CD20-positive B-cell non-Hodgkin lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CD47-targeted therapy
previously received targeted CD47 ... therapy
Cannot have received: SIRPA-targeted therapy
previously received ... signal regulatory protein α (SIRRP α) therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
received allogeneic hematopoietic stem cell transplantation (HSCT)
Cannot have received: organ transplantation
other organ transplantation
Lab requirements
Blood counts
ANC ≥1.0×10^9/L; Platelets ≥75×10^9/L (if bone marrow invasion doesn't exist)/≥50.0×10^9/L (if bone marrow invasion exists); Hemoglobin ≥90 g/L; International Standardized ratio and activated partial thromboplastin time ≤1.5 × ULN
Kidney function
Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min
Liver function
Total bilirubin ≤1.5×ULN, alanine aminotransferase ≤2.5×ULN, aspartate aminotransferase ≤2.5×ULN; Subjects with liver lesion: TBIL≤3×ULN, ALT≤5×ULN, AST≤5×ULN
Suitable organ and hematopoietic function: ... see criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify